CV Safety of Abaloparatide in Postmenopausal Osteoporosis CV Safety of Abaloparatide in Postmenopausal Osteoporosis
A new analysis provides insight into the cardiovascular safety profile of abaloparatide, a medication used to treat osteoporosis in postmenopausal women.Journal of Clinical Endocrinology & Metabolism
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news
More News: Cardiology | Cardiovascular | Diabetes | Endocrinology | Health | Heart | Orthopaedics | Osteoporosis | Women